These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32026409)

  • 1. Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study.
    Ray R; Hahn B; Stanford RH; White J; Essoi B; Hunter AG
    Pulm Ther; 2019 Dec; 5(2):191-200. PubMed ID: 32026409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study.
    Hahn B; Stanford RH; Goolsby Hunter A; Essoi B; White J; Ray R
    Pulm Ther; 2019 Jun; 5(1):69-80. PubMed ID: 32026428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study.
    Hahn B; Stanford RH; Hunter AG; White J; Essoi B; Ray R
    Pulm Ther; 2019 Dec; 5(2):179-190. PubMed ID: 32026410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
    Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC; Stemkowski S; Stanford RH; Tao Z
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of Clinical COPD Questionnaire in Patients with COPD: A Cross-Sectional Observational Study.
    Zhou Z; Zhou A; Peng Y; Duan J; Zeng Y; Zhao Y; Cheng W; Chen P
    Respiration; 2020; 99(7):606-616. PubMed ID: 32659763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GOLD Classification of COPD: Discordance in Criteria for Symptoms and Exacerbation Risk Assessment.
    Mittal R; Chhabra SK
    COPD; 2017 Feb; 14(1):1-6. PubMed ID: 27723367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting.
    Bollmeier SG; Seaton TL; Prosser TR; Chou YT; Reckenberg K; Hahn B; Stanford RH; Ray R
    J Am Pharm Assoc (2003); 2019; 59(4):479-488.e1. PubMed ID: 31126830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members.
    Pasquale MK; Xu Y; Baker CL; Zou KH; Teeter JG; Renda AM; Davis CC; Lee TC; Bobula J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():111-21. PubMed ID: 26834468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients.
    Song Q; Zhao YY; Zeng YQ; Liu C; Cheng W; Deng MH; Li X; Ma LB; Chen Y; Cai S; Chen P
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1401-1412. PubMed ID: 34040367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
    Shin HJ; Kim YI; Kim Y; Lee CY; Ra SW; Moon JY; Jung KS; Yoo KH; Shin KC; Lim SC;
    Chonnam Med J; 2023 Sep; 59(3):180-187. PubMed ID: 37840676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity.
    Mapel DW; Dalal AA; Johnson PT; Becker LK; Hunter AG
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1477-86. PubMed ID: 26251587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses.
    Kim S; Oh J; Kim YI; Ban HJ; Kwon YS; Oh IJ; Kim KS; Kim YC; Lim SC
    BMC Pulm Med; 2013 Jun; 13():35. PubMed ID: 23731868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
    Hsieh MJ; Chen NH; Cheng SL; Tao CW; Wei YF; Wu YK; Chan MC; Liu SF; Hsu WH; Yang TM; Lin MS; Liu CL; Kuo PH; Tsai YH
    Int J Chron Obstruct Pulmon Dis; 2022; 17():967-976. PubMed ID: 35510163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
    Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
    Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population.
    Liu D; Song Q; Zeng Y; Yi R; Liu Y; Li X; Chen Y; Cai S; Chen P
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1741-1751. PubMed ID: 37599897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.